The Pharmaceutical business continues to be a hotbed of innovation, with exercise pushed by the evolution of latest therapy paradigms, the gravity of unmet wants, in addition to the rising significance of applied sciences comparable to pharmacogenomics, digital therapeutics, and synthetic intelligence. Within the final three years alone, there have been over 633,000 patents filed and granted within the pharmaceutical business, in keeping with GlobalData’s report on Robotics in Prescribed drugs: Microneedles for transdermal drug supply.Â
Nonetheless, not all improvements are equal, nor do they observe a continuing upward pattern. As a substitute, their evolution takes the type of an S-shaped curve that displays their typical lifecycle from early emergence to accelerating adoption earlier than lastly stabilising and reaching maturity.Â
Figuring out the place a specific innovation is on this journey, particularly these which are within the rising and accelerating phases, is crucial for understanding their present stage of adoption and the probably future trajectory and impression they are going to have.Â
100 improvements will form the pharmaceutical businessÂ
In accordance with GlobalData’s Expertise Foresights, which plots the S-curve for the pharmaceutical business utilizing innovation depth fashions constructed on over 756,000 patents, there are 110 innovation areas that can form the way forward for the business.Â
Throughout the rising innovation stage, programmable temperature regulation, microreactor automation, and automatic lab analysers are disruptive applied sciences which are within the early phases of utility and ought to be tracked intently. Microneedles for transdermal drug supply, tissue culturing automation, and programmable sterilisation are among the accelerating innovation areas, the place adoption has been steadily rising. Â
Innovation S-curve for robotics within the pharmaceutical businessÂ

Microneedles for transdermal drug supply is a key innovation space in roboticsÂ
Microneedles are sterilised micron-sized, minimally invasive novel drug supply needles used to manage therapeutic brokers. Other than transdermal drug supply purposes, its utilization has prolonged to intraocular, cardiovascular, gastrointestinal, intracochlear, lymphatic, and vaginal supply of medication.Â
GlobalData’s evaluation additionally uncovers the businesses on the forefront of every innovation space and assesses the potential attain and impression of their patenting exercise throughout completely different purposes and geographies. In accordance with GlobalData, there are 100+ firms, spanning expertise distributors, established pharmaceutical firms, and up-and-coming start-ups, engaged within the growth and utility of microneedles for transdermal drug supply.Â
Key gamers in microneedles for transdermal drug supply – a disruptive innovation within the pharmaceutical business Â
 Â
‘Utility range’ measures the variety of completely different purposes recognized for every related patent and broadly splits firms into both ‘area of interest’ or ‘diversified’ innovators.Â
‘Geographic attain’ refers back to the variety of completely different nations every related patent is registered in and displays the breadth of geographic utility supposed, starting from ‘international’ to ‘native.’Â
Sorrento Therapeutics is the main patent filer in microneedles drug supply, adopted by Hisamitsu Pharmaceutical and Kimberly-Clark . Sorrento Therapeutics lately acquired Sofusa, a lymphatic microneedles supply platform, from Kimberly-Clark . The corporate has additionally lately entered a licensing settlement with the Mayo Clinic for a Section 1b pilot examine on utilizing Sofusa lymphatic microneedle to ship Ipilimumab in sufferers with melanoma.
By way of utility range, Broadcom is the highest firm, adopted by Endoderma and PCI Biotech. By the use of geographic attain, Radius Well being holds the highest place. Grifols and Ichor Medical Techniques are within the second and third positions, respectively.
To additional perceive the important thing themes and applied sciences disrupting the pharmaceutical business, entry GlobalData’s newest thematic analysis report on Pharmaceutical.